ReviewArchives of microbiology2026
Beyond new pills: integrative strategies to overcome multidrug-resistant bacteria.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mild-condition green synthesis of manganese nanoparticles for next-generation broad-spectrum antibacterial applications.RSC advances · 2026Article
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
- Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.Archives of microbiology · 2026Review
- Nano-enabled disruption of bacterial virulence and communication in plant pathosystems: emerging strategies for sustainable disease management.Frontiers in plant science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relentless global spread of multidrug-resistant (MDR) bacteria has outpaced the discovery of new antimicrobials, threatening to reverse decades of medical progress. The diminishing efficacy of traditional antibiotics underscores the urgent need for transformative, integrative strategies that combine innovative therapeutics, precision diagnostics, advanced delivery platforms and global policy interventions. This review examines recent advances and emerging technologies designed to overcome MDR pathogens. We synthesize developments in next-generation antibiotics, bacteriophage and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) based therapies, antimicrobial peptides (AMPs), nanotechnology-enabled delivery systems, rapid molecular diagnostics and artificial intelligence (AI)-driven drug discovery. We also assess host-directed approaches, anti-virulence strategies and biofilm disruption techniques that complement traditional antibacterial interventions. Finally, we address the implementation science underlying stewardship, surveillance, and policy reforms required to sustain innovation and equitable access. We argue that the path forward will depend not on a single discovery but on a convergent ecosystem of biological, technological and policy innovations that together can outmaneuvre bacterial evolution.
Indexed as
Identifiers
41843109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.